Rheumatoid Arthritis Treatment Help Slow or Stop the Disease Symptoms And Prevent Further Damage to the Joints
Rheumatoid Arthritis Treatment |
Rheumatoid Arthritis is an autoimmune disease, which
means that the immune system of an individual mistakenly attacks body’s own
cells and tissues. The symptoms of RA may vary from mild to severe, and they
can impact the quality of patient’s life. Rheumatoid arthritis treatment can
slow or stop the symptoms and prevent further damage to the joints and other
organs.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly
used as Rheumatoid
Arthritis Treatment. They decrease inflammation and can ease
pain, however they do not cure the condition. NSAIDs come in over-the-counter
and prescription varieties, including ibuprofen (Advil, Motrin) and naproxen
sodium (Aleve). They are safe to use and usually have few side effects.
Intra-articular corticosteroids, or steroids injected into
the joint, can also be effective for controlling flare-ups of RA. They can be
used for several months or a few weeks at a time, depending on the severity of the
symptoms.
DMARDs, or disease-modifying antirheumatic drugs, can help
slow the progression of rheumatoid arthritis by lowering the body’s immune
response to the damage it causes to the joints. These include methotrexate
(Trexall, Otrexup), leflunomide (Arava), hydroxychloroquine (Plaquenil), and
sulfasalazine (Azulfidine).
They are often given in combination with other DMARDs to
maximize their effect on patient’s Rheumatoid
Arthritis. The doctor will start patient on a lower dose and increase it
over a few months as their symptoms improve.
Rheumatoid Arthritis
Treatment drugs reduce the production of
inflammatory chemicals called cytokines. Cytokines have an important role in RA
by increasing the amount of white blood cells called lymphocytes that attack
and destroy joint tissue and other body parts. IL-1, another inflammatory
cytokine, also contributes to the development of RA. IL-1 antagonists block the
IL-1 receptor, which makes it less effective at stimulating the inflammatory
process. This is why IL-1 blockers can be useful for treating RA, especially
for people who have been on steroid medications for a long time and who are not
getting the full benefit of their treatments. In November 2022, Eisai Co. Ltd.
and Nippon Medac Co. Ltd. announced the launch of the anti-rheumatic agent
“Metoject” Subcutaneous Injection 15 mg syring 0.30 mL, 12.5mg syring 0.25mL,
10mg syring 0.20mL, and 7.5mg syringe 0.15mL, in Japan for RA treatment.
Comments
Post a Comment